BioCentury | Aug 17, 2019
Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
BC Innovations | Jun 7, 2019
Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
BC Week In Review | Jan 25, 2019
Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
BC Extra | Jan 24, 2019
Company News

Vertex builds CRISPR toolbox with Merck KGaA deal

In its latest move to build its gene editing capabilities, Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in-licensed from Merck KGaA (Xetra:MRK) rights to two DNA damage response (DDR) inhibitors for gene editing applications. While Merck has been...
BC Innovations | Nov 6, 2018
Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer, pancreatic cancer Patient sample and mouse studies suggest combining DNA-PK inhibitors with the oncolytic alphavirus M1 could help treat colorectal and pancreatic cancers. In colorectal tumor cells from patients, a DNA-PK inhibitor...
BC Innovations | Jun 20, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella...
BC Week In Review | Jun 15, 2017
Clinical News

Merck reports Phase Ia data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 7 evaluable patients with advanced solid tumors or metastases including lymphoma localized in the head and neck region or thorax in the Phase Ia portion of a Phase Ia/Ib...
BC Week In Review | Jun 15, 2017
Clinical News

Merck reports Phase I data for DNA-PK inhibitor M3814 in solid tumors

Merck KGaA (Xetra:MRK) reported data from 25 evaluable patients with advanced solid tumors in a Phase I trial showing that oral M3814 (MSC 2490484A) led to 6 cases of stable disease lasting for ≥18 weeks....
BC Week In Review | Jan 13, 2017
Company News

Vertex, Merck deal

Vertex granted Merck exclusive, worldwide rights to four cancer programs. Vertex will receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs' development and commercialization. The deal includes...
BC Extra | Jan 12, 2017
Company News

Vertex grants Merck KGaA rights to cancer programs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) granted Merck KGaA (Xetra:MRK) exclusive, worldwide rights to four cancer programs. Vertex is to receive $230 million up front and is eligible for royalties. Merck will be responsible for the programs'...
Items per page:
1 - 10 of 16